Compare TKNO & CGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TKNO | CGC |
|---|---|---|
| Founded | 1996 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 482.7M | 389.2M |
| IPO Year | 2021 | 2023 |
| Metric | TKNO | CGC |
|---|---|---|
| Price | $9.00 | $0.88 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 3 |
| Target Price | ★ $9.00 | $1.95 |
| AVG Volume (30 Days) | 254.4K | ★ 2.0M |
| Earning Date | 11-05-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 43.86 | ★ 84.17 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $40,520,000.00 | $12,759,000.00 |
| Revenue This Year | $13.53 | $21.39 |
| Revenue Next Year | $14.01 | $8.33 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.35 | N/A |
| 52 Week Low | $1.91 | $0.84 |
| 52 Week High | $9.48 | $2.38 |
| Indicator | TKNO | CGC |
|---|---|---|
| Relative Strength Index (RSI) | 71.35 | 34.55 |
| Support Level | $4.87 | $0.85 |
| Resistance Level | $9.48 | $0.98 |
| Average True Range (ATR) | 0.53 | 0.03 |
| MACD | 0.06 | -0.00 |
| Stochastic Oscillator | 87.63 | 16.38 |
Alpha Teknova Inc is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Its offer two primary product categories: Lab Essentials and Clinical Solutions. It derives key revenue from the United States. The company offers three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid microbial culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification.
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.